PE20120049A1 - Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek - Google Patents

Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek

Info

Publication number
PE20120049A1
PE20120049A1 PE2011001541A PE2011001541A PE20120049A1 PE 20120049 A1 PE20120049 A1 PE 20120049A1 PE 2011001541 A PE2011001541 A PE 2011001541A PE 2011001541 A PE2011001541 A PE 2011001541A PE 20120049 A1 PE20120049 A1 PE 20120049A1
Authority
PE
Peru
Prior art keywords
inhibitors
alkyl
aniline
pyridine
derivatives
Prior art date
Application number
PE2011001541A
Other languages
English (en)
Inventor
Stephen Price
Karen Williams
Pascal Pierre Savy
Hazel Joan Dyke
John Gary Montana
Mark S Stanley
Liang Bao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20120049A1 publication Critical patent/PE20120049A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE AZABENZOTIOFENIL DE FORMULA (I) DONDE Z1 ES CR1; Z2 ES N; Z3 ES CR3; Z4 ES CR4, EN DONDE R1, R3 Y R4 SON CADA UNO H, HALO, CN, CF3, NO2, ENTRE OTROS; W ES NX1R5 O OR11, EN DONDE R5 Y R6 SON CADA UNO H O ALQUILO(C1-12); X1 ES OR11 O R11, DONDE R11 ES H, ALQUILO(C1-C12), ALQUENILO(C2-C8), ENTRE OTROS; X2 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO O SR16, EN DONDE R16 ES H, ALQUILO(C1-C12) O ALQUENILO(C2-C8). TAMBIEN SE REFIERE A UNA COMPOSION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE LA QUINASA MEK SIENDO UTILES EN EL TRATAMIENTO DE CANCER, ARTRITIS REUMATOIDE
PE2011001541A 2006-08-21 2007-08-21 Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek PE20120049A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83916306P 2006-08-21 2006-08-21
US87160006P 2006-12-22 2006-12-22
US91762407P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
PE20120049A1 true PE20120049A1 (es) 2012-02-16

Family

ID=38800915

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001134A PE20081359A1 (es) 2006-08-21 2007-08-21 Compuestos de azabenzotiofenil como inhibidores de la quinasa mek
PE2011001541A PE20120049A1 (es) 2006-08-21 2007-08-21 Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2007001134A PE20081359A1 (es) 2006-08-21 2007-08-21 Compuestos de azabenzotiofenil como inhibidores de la quinasa mek

Country Status (16)

Country Link
US (1) US7893085B2 (es)
EP (1) EP2069359B1 (es)
JP (1) JP5349306B2 (es)
KR (1) KR101475088B1 (es)
AR (1) AR062469A1 (es)
AU (1) AU2007286807B2 (es)
BR (1) BRPI0714629A2 (es)
CA (1) CA2660963A1 (es)
CL (1) CL2007002431A1 (es)
ES (1) ES2528797T3 (es)
IL (1) IL197060A (es)
MX (1) MX2009001875A (es)
NO (1) NO20091198L (es)
PE (2) PE20081359A1 (es)
TW (1) TWI426078B (es)
WO (1) WO2008024724A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085886A1 (en) * 2006-08-21 2008-04-10 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
AU2011221227B2 (en) 2010-02-25 2015-07-09 Dana-Farber Cancer Institute, Inc. BRAF mutations conferring resistance to BRAF inhibitors
CA2791247C (en) 2010-03-09 2019-05-14 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
WO2013164769A1 (en) 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2014071183A1 (en) 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
SG11201804901WA (en) * 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
JP7212956B2 (ja) 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン－アニリン化合物
MA49140A (fr) * 2017-05-19 2020-03-25 Nflection Therapeutics Inc Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
CA3073073A1 (en) 2017-09-08 2019-03-14 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US11572344B2 (en) 2018-11-20 2023-02-07 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113825543A (zh) 2019-03-19 2021-12-21 勃林格殷格翰动物保健美国公司 驱虫的氮杂-苯并噻吩和氮杂-苯并呋喃化合物
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328920A (en) 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
WO1993001169A2 (en) 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5214204A (en) 1991-07-19 1993-05-25 Abbott Laboratories Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity
DE69216509T2 (de) 1991-08-12 1997-05-28 Takeda Chemical Industries Ltd Kondensierte Pyrimidinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5350748A (en) 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
DE4425609A1 (de) 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
JP4306806B2 (ja) 1997-04-24 2009-08-05 ダウ・アグロサイエンス・エル・エル・シー 有害生物防除性 ３―（置換フェニル）―５―（チエニルまたはフリル）―１，２，４―トリアゾール
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2777886B1 (fr) 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002519321A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
CA2335310A1 (en) 1998-06-30 2000-01-06 Kenneth Lee Hauser Azepine derivatives having effects on serotonin related systems
ATE225345T1 (de) 1998-06-30 2002-10-15 Lilly Co Eli Auf serotonin-verwandte systeme wirkende piperidin-derivate
US6410562B1 (en) 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
ATE302193T1 (de) * 1999-01-13 2005-09-15 Warner Lambert Co Benzoheterozyklen und ihre verwendung als mek inhibitoren
FR2799756B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
AU2001273498B2 (en) 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
JP2005523287A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療用アザビシクロ化合物
SG148857A1 (en) * 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
UA76837C2 (uk) * 2002-03-13 2006-09-15 Еррей Байофарма Інк. N3 алкіловані похідні бензімідазолу як інгібітори мек
US20040009976A1 (en) 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
DE602004032446D1 (de) 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
DE10351436A1 (de) 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2005054176A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2005058858A1 (en) 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
WO2005061476A2 (en) 2003-12-22 2005-07-07 Basilea Pharmaceutica Ag Aroylfuranes and aroylthiophenes
CA2549638A1 (en) 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
CA2601983A1 (en) * 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
EP1934228A2 (en) * 2005-09-01 2008-06-25 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
US20080085886A1 (en) 2006-08-21 2008-04-10 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008028141A2 (en) 2006-08-31 2008-03-06 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof

Also Published As

Publication number Publication date
AR062469A1 (es) 2008-11-12
KR101475088B1 (ko) 2014-12-23
EP2069359A1 (en) 2009-06-17
NO20091198L (no) 2009-05-20
CL2007002431A1 (es) 2008-03-14
KR20090047538A (ko) 2009-05-12
CA2660963A1 (en) 2008-02-28
PE20081359A1 (es) 2008-11-27
US20080081821A1 (en) 2008-04-03
BRPI0714629A2 (pt) 2013-05-07
EP2069359B1 (en) 2014-11-12
IL197060A0 (en) 2009-11-18
US7893085B2 (en) 2011-02-22
JP2010501584A (ja) 2010-01-21
IL197060A (en) 2014-12-31
AU2007286807A1 (en) 2008-02-28
JP5349306B2 (ja) 2013-11-20
WO2008024724A1 (en) 2008-02-28
TWI426078B (zh) 2014-02-11
ES2528797T3 (es) 2015-02-12
MX2009001875A (es) 2009-03-02
TW200823222A (en) 2008-06-01
AU2007286807B2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
PE20120049A1 (es) Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20091527A1 (es) Derivados de piridazinona
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
GB0510584D0 (en) Organic compounds
PE20130647A1 (es) Indoles
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
NO20070731L (no) Heterocykliske forbindelser.
PE20140397A1 (es) Derivados de fluoro-piridinona utiles como agentes antibacterianos
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20090775A1 (es) Nuevos derivados de biarilo
PE20121482A1 (es) Derivados de imidazopiridina como inhibidores de jak
PE20090610A1 (es) Derivados de pirazol sustituidos
PE20091158A1 (es) 5-anilinoimidazopiridinas y metodos de uso
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20110424A1 (es) Isoindolonas que inhiben la cinasa mek
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
PE20090238A1 (es) Derivados de pirazol como inhibidores de tirosinquinasas
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20081174A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed